Safety and Tolerability of ShigActive™, a <i>Shigella</i> spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial

• Ngā kaituhi matua: Wilbur H. Chen (Author), Joelle Woolston (Author), Silvia Grant-Beurmann (Author), Courtney K. Robinson (Author), Garima Bansal (Author), Joseph Nkeze (Author), Jasnehta Permala-Booth (Author), Claire M. Fraser (Author), Sharon M. Tennant (Author), Mallory C. Shriver (Author), Marcela F. Pasetti (Author), Yuanyuan Liang (Author), Karen L. Kotloff (Author), Alexander Sulakvelidze (Author), Jennifer A. Schwartz (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2024-09-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Bacterial diseases of the gastrointestinal (GI) tract continue to be a major worldwide cause of human morbidity and mortality. Among various enteric pathogens, <i>Shigella</i> spp. are some of the most common and deadly bacterial pathogens. They are responsible for ~125 million worldwide...